Current AD detection methods mainly include the determination of Aβ, tau, or phosphorylated tau levels in the CSF with invasive diagnostic procedures (He et al., 2010) and imaging techniques such as functional magnetic resonance imaging or positron emission tomography scans (Hare et al., 2015) during the late stages of the disease. This evidence concerns the gene MAPT and Alzheimer disease.